Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The